$1.66
+0.10 (+6.41%)
Open$1.60
Previous Close$1.56
Day High$1.73
Day Low$1.59
52W High$25.72
52W Low$14.02
Volume—
Avg Volume126.2K
Market Cap114.05M
P/E Ratio—
EPS$-1.91
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+1,081.3% upside
Current
$1.66
$1.66
Target
$19.61
$19.61
$14.26
$19.61 avg
$29.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.68M | 29.02M | 30.84M |
| Net Income | -234,624 | -227,719 | -278,307 |
| Profit Margin | -0.9% | -0.8% | -0.9% |
| EBITDA | -236,384 | -290,155 | -260,150 |
| Free Cash Flow | -281,986 | -255,634 | -361,408 |
| Rev Growth | +16.9% | +16.9% | +11.1% |
| Debt/Equity | 0.63 | 0.72 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |